D&A at other companies
Other financials
Where this comes from
Reported directly by TriSalus Life Sciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.
The official record: TriSalus Life Sciences, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about TriSalus Life Sciences, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is TriSalus Life Sciences, Inc.'s D&A?
- TriSalus Life Sciences, Inc. (TLSI) reported D&A of $135K in Q1 2026.
- How has TriSalus Life Sciences, Inc.'s D&A changed year-over-year?
- TriSalus Life Sciences, Inc.'s D&A decreased by 21.5% year-over-year, from $172K to $135K.
- What is the long-term trend for TriSalus Life Sciences, Inc.'s D&A?
- Over 3 years (2022 to 2025), TriSalus Life Sciences, Inc.'s D&A has grown at a 16.3% compound annual growth rate (CAGR), from $398K to $626K.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.